4-HO-MiPT

4-HO-MiPT appears by name in Lista F2 of the current Anexo I to Portaria SVS/MS nº 344/1998, the list of psychotropic substances whose use is proscribed in Brazil. ANVISA added it to that list by Resolução RDC nº 246, dated 21 August 2018, which takes effect on the date of its publication in the Diário Oficial da União of 22 August 2018.⁶ Under Lei nº 11.343/2006, substances on lists kept periodically by the federal executive are drugs, and drugs are prohibited throughout the national territory except where legal or regulatory authorization applies. Acquiring, keeping, storing, transporting, or carrying the drug for personal consumption without authorization draws the Article 28 measures of a warning about the effects of drugs, community service, and attendance at an educational programme or course. Importing, exporting, producing, selling, offering, storing, transporting, prescribing, supplying, or delivering it for consumption without authorization falls under Article 33, punishable by five to fifteen years' imprisonment and 500 to 1,500 day-fines. Import and export of 4-HO-MiPT analytical standards holding no more than 500 mg of the controlled substance per unit require no import or export authorization.

The exact identity is expressly named in the current MHLW designated-drug list, including its salts. The current MHLW narcotic designation PDF and the current e-Gov narcotic designation decree do not expressly classify the exact name as a narcotic; the applicable classification is the expressly named designated-drug entry. Ordinary handling is prohibited outside legally specified medical or other permitted uses.

4-HO-MiPT is expressly named in Poland's current Annex 3 Part 1 NPS schedule as item 34, rather than being merely an unlisted analogue. Article 62b makes possession contrary to the Act punishable by a fine, with enhanced penalties for a significant quantity; the own-use discontinuance clause is discretionary and does not legalize possession. Commercial handling and market placement require substance-specific authorization under Article 40a, while the schedule's concluding clause covers possible salts and stereoisomers. The schedule amendment in Dz.U. 2026 poz. 934 does not alter item 34.

4-HO-MiPT is a hälsofarlig vara in Sweden. Förordning (2005:733) added 4-hydroxi-N,N-metylisopropyltryptamin (4-HO-MIPT) to the bilaga of förordningen (1999:58) om förbud mot vissa hälsofarliga varor with effect from 1 November 2005.²³ Listing is done by the Government through that bilaga, and 2 § of the förordning provides that the goods named there are hälsofarliga varor under lagen (1999:42) om förbud mot vissa hälsofarliga varor, whose 1 § leaves it to the Government to prescribe which goods the Act applies to. The bilaga as amended through SFS 2026:1110 still lists the substance, and salts of the listed substances fall under the listing where such salts occur. Under 3 § lagen (1999:42) goods covered by the Act may not without a permit be imported into the country, transferred, manufactured, acquired for the purpose of transfer, offered for sale or possessed, nor procured, processed, packaged, transported, stored or otherwise handled where they are not intended for personal use. Folkhälsomyndigheten grants permits for handling for a scientific or industrial purpose under 4 § förordningen (1999:58), may issue regulations exempting conduct from the permit requirement, and supervises compliance with the Act. Intentional transfer, manufacture, acquisition for the purpose of transfer, other handling not intended for personal use, offering for sale or possession without a permit carries a fine or imprisonment for up to one year under 4 § lagen (1999:42), and the same conduct apart from possession carries a fine or imprisonment for up to six months when committed through gross negligence, with no liability in petty cases. Failure to keep the records required by 3 a § or to mark the substance name on the packaging under 3 b § carries a fine, and penalties for unlawful importation follow lagen (2000:1225) om straff för smuggling.

4-HO-MiPT is controlled in the United Kingdom under the generic tryptamine provision; group or analogue treatment remains dependent on the cited statutory scope.

4-HO-MiPT is not expressly listed in 21 CFR § 1308.11, 21 U.S.C. § 812(c), or the DEA August 2026 alphabetical reference. The DEA's nearby DET row separately identifies unsubstituted MiPT as a positional isomer of DET; it does not name 4-HO-MiPT. Federal Analogue Act treatment is conditional, not automatic: 21 U.S.C. §§ 802(32)(A) and 813 require the statutory similarity and effect or representation analysis and limit Schedule I treatment to the extent intended for human consumption; those provisions do not decide those facts for every sample or transaction. State law is not uniform. North Carolina, Florida, Illinois, New Mexico, and West Virginia expressly list 4-HO-MiPT or its exact full chemical identity in Schedule I. These are state-specific examples only; no all-state inference follows, and the particular state, conduct, exceptions, and facts must be checked before reaching a legality conclusion.

4-HO-MiPT is controlled in Germany under the NpSG tryptamine-group provision; group or analogue treatment remains dependent on the cited statutory scope.

4-HO-MIPT is expressly named in the current binding Swiss Annex 6 Verzeichnis e schedule as a raw material/product with presumed narcotic-like effect. This is a controlled-products category: Article 7 requires EDI authorization for the listed activities and Article 20(1)(c) penalizes those activities without authorization, but an unqualified blanket possession prohibition for Verzeichnis e entries is not established. The category is restricted and subject to applicable statutory authorizations and conduct-specific exceptions.